Access the full text.
Sign up today, get DeepDyve free for 14 days.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
ORIGINAL ARTICLE Oral Vinorelbine and Cisplatin as Induction Chemotherapy and Concomitant Chemo-Radiotherapy in Stage III Non-small Cell Lung Cancer Final Results of an International Phase II Trial Maciej Krzakowski, MD, Mariano Provencio, MD, Beata Utracka-Hutka, MD,† Eugenio Villa, MD, Manuel Codes, MD, Abraham Kuten, MD, Michael Henke, MD, Massimo Lopez, MD, David Bell, MD, Giampaolo Biti, MD, Ofer Merimsky, MD, Aulo Beorchia, MD, Marcello Riggi, MD, Noe¨l-Raphae¨l Caux, MSc, Jean-Christophe Pouget, MSc, Bernard Dubray, MD, and Philippe David, MD 86%/93% and 97%/98% at induction and in combination with Introduction: Cisplatin in combination with vinorelbine has re- radiotherapy, respectively. Forty-one patients (76%) increased oral ported an optimal activity/tolerance ratio when used in combination vinorelbine from 60 to 80 mg/m day during induction (reasons for with radiotherapy in locally advanced unresectable non-small cell nonescalation: hematological 7 patients, nonhematological 2 pa- lung cancer. The currently available oral formulation of vinorelbine tients, error 4 patients). After two cycles of chemotherapy induction, should be easier to use assuming a similar activity profile. An the OR intent-to-treat in the 54 patients was 37%. Toxicities during international phase II trial with vinorelbine oral and cisplatin as induction were as follows: Neutropenia G3–4 (28%), Febrile Neu- induction
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: Sep 1, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.